TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)
Brief Summary: The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation. Abstinence from cigarette smoking and other tobacco products (e.g., pipe, cigars, chew, snuff.) use during non-treatment follow-up period will also be evaluated.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Varenicline + Placebo Patch; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Placebo Patch, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Arm Label: Nicotine Patch + Placebo Tablet; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Placebo Tablet, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: DRUG; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Placebo Tablet; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: BEHAVIORAL; Name: Questionnaires; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: BEHAVIORAL; Name: Counseling Sessions; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Lab Session; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Saliva Test; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)
Brief Summary: The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation. Abstinence from cigarette smoking and other tobacco products (e.g., pipe, cigars, chew, snuff.) use during non-treatment follow-up period will also be evaluated.


Options:
A: Arm Label: 1 Nix Individual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nix Individual | Arm Label: 2 Fimpa dig fri; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Fimpa dig fri | Intervention Type: BEHAVIORAL; Name: Nix Individual; Assigned to Arm(s): 1 Nix Individual | Intervention Type: BEHAVIORAL; Name: Fimpa dig fri; Assigned to Arm(s): 2 Fimpa dig fri
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: 5 A | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: 3 A | Intervention Type: BEHAVIORAL; Name: 5 A; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: 3 A; Assigned to Arm(s): 3
D: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)
Brief Summary: The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation. Abstinence from cigarette smoking and other tobacco products (e.g., pipe, cigars, chew, snuff.) use during non-treatment follow-up period will also be evaluated.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Varenicline + Placebo Patch; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Placebo Patch, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Arm Label: Nicotine Patch + Placebo Tablet; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Placebo Tablet, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: DRUG; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Placebo Tablet; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: BEHAVIORAL; Name: Questionnaires; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: BEHAVIORAL; Name: Counseling Sessions; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Lab Session; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Saliva Test; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT.
Brief Summary: The aim of this study is to discontinue antipsychotics and antidepressants, and to study its effect on Behavioural- and Psychological Symptoms in Dementia (BPSD).


Options:
A: Arm Label: Advance care planning intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Advance care planning intervention | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Advance care planning intervention; Assigned to Arm(s): Advance care planning intervention | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Usual care
B: Arm Label: Galantamine; Type: EXPERIMENTAL; Interventions: Drug: Galantamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Galantamine; Assigned to Arm(s): Galantamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Risperidone, Drug: Escitalopram, Drug: Citalopram, Drug: Sertraline, Drug: Paroxetine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): A
D: Arm Label: Risperidone-risperidone; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Risperidone-Placebo; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Placebo-Placebo; Type: OTHER; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Placebo-Placebo, Risperidone-Placebo, Risperidone-risperidone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT.
Brief Summary: The aim of this study is to discontinue antipsychotics and antidepressants, and to study its effect on Behavioural- and Psychological Symptoms in Dementia (BPSD).


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Risperidone, Drug: Escitalopram, Drug: Citalopram, Drug: Sertraline, Drug: Paroxetine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): A
B: Arm Label: Supported Protocolized Discontinuation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD) | Arm Label: SPD + Mindfulness (MBCT); Type: EXPERIMENTAL; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD), Behavioral: Mindfulness Based Cognitive Therapy (MBCT) | Intervention Type: BEHAVIORAL; Name: Supported Protocolized Discontinuation (SPD); Assigned to Arm(s): SPD + Mindfulness (MBCT), Supported Protocolized Discontinuation | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy (MBCT); Assigned to Arm(s): SPD + Mindfulness (MBCT)
C: Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A
D: Arm Label: Cognitive therapy plus medications; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Therapy, Drug: Medications | Arm Label: Medications alone; Type: EXPERIMENTAL; Interventions: Drug: Medications | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): Cognitive therapy plus medications | Intervention Type: DRUG; Name: Medications; Assigned to Arm(s): Cognitive therapy plus medications, Medications alone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT.
Brief Summary: The aim of this study is to discontinue antipsychotics and antidepressants, and to study its effect on Behavioural- and Psychological Symptoms in Dementia (BPSD).


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Risperidone, Drug: Escitalopram, Drug: Citalopram, Drug: Sertraline, Drug: Paroxetine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): A
B: Arm Label: Galantamine; Type: EXPERIMENTAL; Interventions: Drug: Galantamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Galantamine; Assigned to Arm(s): Galantamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: galantamine hydrobromide; Assigned to Arm(s): N/A
D: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Fitness in Older Overweight Vets With Impaired Fasting Glucose
Brief Summary: This study targets older adults (ages 60 and over) who are overweight (body mass index 25-40) with impaired fasting glucose (100 - 125). We propose a three-year, randomized controlled clinical trial (n=300) to determine the effect of a one-year physical activity counseling intervention on glucose metabolism and secondary outcomes compared to usual care.


Options:
A: Arm Label: Telemedicine; Type: OTHER; Interventions: Other: Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: Arm 1 Physical Activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Counseling | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Counseling; Assigned to Arm(s): Arm 1 Physical Activity counseling
C: Arm Label: Home Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Intel Health Guide | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Intel Health Guide; Assigned to Arm(s): Home Telemonitoring | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Fitness in Older Overweight Vets With Impaired Fasting Glucose
Brief Summary: This study targets older adults (ages 60 and over) who are overweight (body mass index 25-40) with impaired fasting glucose (100 - 125). We propose a three-year, randomized controlled clinical trial (n=300) to determine the effect of a one-year physical activity counseling intervention on glucose metabolism and secondary outcomes compared to usual care.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care and Reading Materials | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Modification Program | Intervention Type: BEHAVIORAL; Name: Lifestyle Modification Program; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Usual Care and Reading Materials; Assigned to Arm(s): 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Delayed intervention | Intervention Type: BEHAVIORAL; Name: Early Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Delayed intervention; Assigned to Arm(s): 2
C: Arm Label: CST; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone-based Enhanced Coping Skills Training (CST) | Arm Label: UMC; Type: OTHER; Interventions: Other: Usual Medical Care and COPD education and symptom monitoring (UMC) | Intervention Type: BEHAVIORAL; Name: Telephone-based Enhanced Coping Skills Training (CST); Assigned to Arm(s): CST | Intervention Type: OTHER; Name: Usual Medical Care and COPD education and symptom monitoring (UMC); Assigned to Arm(s): UMC
D: Arm Label: Arm 1 Physical Activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Counseling | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Counseling; Assigned to Arm(s): Arm 1 Physical Activity counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age-Related Eye Disease Study (AREDS) and AREDS2 Follow-Up
Brief Summary: This study is a 5-year extension of the AREDS protocol, in which investigators followed the natural course of age-related macular degeneration (AMD) and cataracts. Participants in the former AREDS protocol are eligible for this study.

Participants have a complete eye examination once a year and are contacted at least once a year between visits to check on their status. The eye examination includes measurement of visual acuity (vision chart test) and examination of the inside of the eye after the pupils have been dilated with eye drops. Photographs of the inside of the eye may be taken using a special camera that flashes a bright light in the eye. A blood sample may be obtained to test for cholesterol level and genes related to inflammation....


Options:
A: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
B: Arm Label: AREDS participants; Type: N/A; Interventions: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 20 µg selenium | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 40 µg selenium | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 60 µg selenium | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 80 µg selenium | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 100 µg selenium | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 120 µg selenium | Arm Label: 7; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 20 µg selenium; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: 40 µg selenium; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: 60 µg selenium; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 80 µg selenium; Assigned to Arm(s): 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: 100 µg selenium; Assigned to Arm(s): 5 | Intervention Type: DIETARY_SUPPLEMENT; Name: 120 µg selenium; Assigned to Arm(s): 6 | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): 7
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Drug: Vitamin E | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Behavioral: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Behavioral: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): 2, 3, 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Closing the Post Fracture Care Gap in Manitoba
Brief Summary: The objective of this study is to evaluate a post-fracture intervention for improving osteoporosis care in older men and women who have suffered a fracture that may indicate the presence of osteoporosis. Although osteoporosis can be identified with a bone mineral density (BMD) test, most individuals with osteoporosis are not diagnosed until they fracture. Post-fracture care often "falls between the cracks" when there is a breakdown in communication between hospital and community, or between specialists and primary care physicians. Often physicians and patients fail to make the connection between an acute fracture and osteoporosis, or the value of secondary prevention strategies. If untreated, there is an extremely high rate of additional fractures after a first osteoporotic fracture. It follows that improving BMD testing and/or treatment in appropriately identified individuals is a necessary step in optimizing post-fracture patient care. Over the next three years we will be testing and optimizing a notification procedure to physicians and/or patients relying upon fracture events reported to the provincial health service (Manitoba Health).


Options:
A: Arm Label: 1 (physician-only); Type: EXPERIMENTAL; Interventions: Other: Information letters | Arm Label: 2 (physician/patient); Type: EXPERIMENTAL; Interventions: Other: Information letters | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Information letters; Assigned to Arm(s): 1 (physician-only), 2 (physician/patient)
B: Intervention Type: BEHAVIORAL; Name: Multifaceted intervention (patient education, physician guidelines, reminders); Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
D: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A

Answer: A